185049-55-2

Upstream product

• 1005106-40-0 C₂₃H₃₂O₆ 
• 939-97-9 4-tert-Butylbenzaldehyde 
• 185049-53-0 3-(4-tert-butylphenyl)glutaric diacid 

Downstream Products

• 420088-66-0 3-(4-tert-butyl-phenyl)-pentanedioic acid 3,17-bis-[3-(4-tert-butyl-phenyl)-4-(2,5-dioxo-pyrrolidin-1-yloxycarbonyl)-butyryloxy]-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-6-yl ester 2,5-dioxo-pyrrolidin-1-yl ester 
• 1221962-44-2 3-(4-tert-butylphenyl)-4-(5-iodo-2-benzimidazolyl)-butanoic acid monohydrochloride 
• 1221962-44-2 3-(4-t-butylphenyl)-4-(5-iodo-2-benzimidazolyl)butanoic acid hydrochloride 
• 198560-58-6 3-(4-tert-Butyl-phenyl)-4-(2-sulfo-ethylcarbamoyl)-butyric acid (3S,5S,6S,8R,9S,10R,13S,14S,17S)-17-[3-(4-tert-butyl-phenyl)-4-(2-sulfo-ethylcarbamoyl)-butyryloxy]-6-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-yl ester 
• 189894-04-0 3-(4-tert-Butyl-phenyl)-4-(2-sulfo-ethylcarbamoyl)-butyric acid (3S,5S,8R,9S,10S,13S,14S,17S)-3-[3-(4-tert-butyl-phenyl)-4-(2-sulfo-ethylcarbamoyl)-butyryloxy]-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl ester 

Relevant academic research and scientific papers

ALLOSTERIC PROTEIN KINASE MODULATORS

The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

4-benzimidazolyl-3-phenylbutanoic acids as novel pif-pocket-targeting allosteric inhibitors of protein kinase PKCΧ

Protein kinase inhibitors with an allosteric mode of action are expected to reach, in many cases, higher selectivity for the target enzyme than ATP-competitive compounds. Therefore, basic research is aiming at identifying and establishing novel sites on the catalytic domain of protein kinases which might be targeted by allosteric inhibitors. We previously published the first structure-activity relationships (SARs) for allosteric activators of protein kinase PDK1. Here, we present the design, synthesis, and SAR data on a series of novel compounds, 4-benzimidazolyl-3-phenylbutanoic acids, that inhibit the atypical protein kinace C (PKC) Χ via binding to the PIF-pocket. Key positions were identified in the compounds that can be modified to increase potency and selectivity. Some congeners showed a high selectivity toward PKCΧ, lacking inhibition of the most closely related isoform, PKC1, and of further AGC kinases. Furthermore, evidence is provided that these compounds are also active toward cellular PKCΧ without loss of potency compared to the cell-free assay.

ALLOSTERIC PROTEIN KINASE MODULATORS

The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

Catalytic oxidations of steroid substrates by artificial cytochrome p-450 enzymes.

Catalysts comprising manganese-porphyrins carrying cyclodextrin binding groups are able to perform hydroxylations with substrate selectivity and regio- and stereoselectivity and high catalytic turnovers. The geometries of the catalyst/substrate complexes override intrinsic substrate reactivities, permitting attack on geometrically accessible saturated carbons of steroids in the presence of secondary carbinol groups and carbon-carbon double bonds, as in enzymatic reactions. Selective hydroxylations of steroid carbon 9 positions are of particular practical interest.